Celldex Therapeutics reported positive Phase 2 trial results for barzolvolimab, a novel antibody targeting mast cells, showing significant and lasting improvements in quality of life for patients with chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD). Patients experienced reduced symptoms and better daily functioning across multiple life domains, with benefits persisting months after treatment ended. These findings support barzolvolimab’s potential as a best-in-class treatment for these difficult-to-treat skin conditions, with Phase 3 trials underway and topline data expected in late 2026.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
